1.Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia.
Vedat GERDAN ; Nurullah AKKOC ; Eyup Sabri UCAN ; Serpil Bulac KIR
Singapore medical journal 2013;54(6):e125-6
We report the case of a 36-year-old man with psoriatic arthritis and miliary tuberculosis, whose serum uric acid (SUA) level increased after the initiation of antituberculosis treatment, which included pyrazinamide. Most strikingly and paradoxically, the patient's SUA level increased after treatment with allopurinol. On cessation of allopurinol, his SUA level decreased substantially, and complete normalisation was observed following the discontinuation of pyrazinamide treatment.
Adult
;
Allopurinol
;
therapeutic use
;
Arthritis, Psoriatic
;
drug therapy
;
Humans
;
Hyperuricemia
;
chemically induced
;
Male
;
Pyrazinamide
;
adverse effects
;
Treatment Outcome
;
Tuberculosis, Miliary
;
drug therapy
;
Uric Acid
;
blood
2.A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis.
Jae Young YOON ; Sun Yang MIN ; Ju Yee PARK ; Seung Goun HONG ; Sang Jong PARK ; So Ya PAIK ; Young Min PARK
The Korean Journal of Hepatology 2008;14(1):97-101
Allopurinol-induced hypersensitivity syndrome is characterized by an idiosyncratic reaction involving multiple-organs, which usually begins 2 to 6 weeks after starting allopurinol. In rare cases, the adverse reactions to allopurinol are accompanied by a variety of liver injury, such as reactive hepatitis, granulomatous hepatitis, vanishing bile duct syndrome, or fulminant hepatic failure. Here we report a case with granulomatous hepatitis and ductopenia. A 69-year-old man with chronic renal failure, hyperuricemia, and previously normal liver function presented with jaundice, skin rash, and fever 2 weeks after taking allopurinol (200 mg/day). In histopathology, a liver biopsy specimen showed mild spotty necrosis of hepatocytes, marked cholestasis in parenchyma, and some granulomas in the portal area. There were vacuolar degeneration in the interlobular bile ducts and ductopenia in the portal tracts. Pathologic criteria strongly suggested the presence of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. The patient fully recovered following the early administration of systemic corticosteroid therapy.
Aged
;
Allopurinol/*adverse effects/therapeutic use
;
Antimetabolites/*adverse effects/therapeutic use
;
Bile Duct Diseases/*chemically induced/diagnosis/pathology
;
Bile Ducts, Intrahepatic/*drug effects/pathology
;
Cholestasis/*chemically induced/diagnosis/pathology
;
Drug Eruptions/pathology
;
Granuloma/*chemically induced/pathology
;
Hepatitis, Toxic/*pathology
;
Humans
;
Kidney Failure, Chronic/complications/drug therapy
;
Male
3.Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.
Hong Ki MIN ; Boin LEE ; Seung Ki KWOK ; Ji Hyeon JU ; Wan Uk KIM ; Young Min PARK ; Sung Hwan PARK
The Korean Journal of Internal Medicine 2015;30(4):521-530
BACKGROUND/AIMS: Allopurinol is a urate-lowering agent that is commonly used to prevent chemotherapy-related hyperuricemia. Allopurinol hypersensitivity syndrome (AHS) is a disorder involving multiple organs, which may be accompanied by cutaneous adverse reactions. We identified the characteristics and clinical outcomes of chemotherapy-associated AHS in patients with hematological malignancies. METHODS: This retrospective single-center study included 26 AHS patients (11 with and 15 without hematological malignancies) admitted to Seoul St. Mary's Hospital. AHS was defined using the criteria of Singer and Wallace. Comparisons were made using the Mann-Whitney U test and Fisher exact test as appropriate. RESULTS: In patients with a hematological malignancy and AHS, statistically significant differences were observed in terms of younger age at onset; shorter duration of exposure; higher starting and maintenance doses of allopurinol; lower incidence of eosinophilia, leukocytosis, and underlying renal insufficiency; and more frequent occurrence of fever compared to AHS patients without a hematological malignancy. Two AHS patients with a hematological malignancy were examined for human leukocyte antigen (HLA)-B typing, but neither patient harbored the HLA-B*5801 allele. All of the patients ceased allopurinol treatment, with most patients making a full recovery. Two patients in the study died; however, these deaths were unrelated to AHS. One patient developed serious sequelae of AHS that required hemodialysis. CONCLUSIONS: Physicians who prescribe allopurinol for the prevention of chemotherapy-related hyperuricemia should be aware of the unique risk of AHS, even in patients with hematological malignancies who do not have known risk factors for AHS. Novel urate-lowering agents should be considered alternative treatments.
Adolescent
;
Adult
;
Age Factors
;
Aged
;
Allopurinol/*adverse effects
;
Antineoplastic Agents/*adverse effects
;
Comorbidity
;
Dose-Response Relationship, Drug
;
Drug Hypersensitivity Syndrome/diagnosis/drug therapy/*etiology
;
Female
;
Glucocorticoids/therapeutic use
;
Gout Suppressants/*adverse effects
;
Hematologic Neoplasms/*drug therapy
;
Humans
;
Hyperuricemia/chemically induced/diagnosis/*prevention & control
;
Male
;
Medical Records
;
Middle Aged
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Treatment Outcome
;
Young Adult